This Article Full Text Full Text (PDF) All Versions of this Article: 34/8/1826    most recent 01.STR.0000083533.81284.0Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hankey, G. J. Articles by Eikelboom, J. W. Search for Related Content PubMed PubMed Citation Articles by Hankey, G. J. Articles by Eikelboom, J. W.

(Stroke. 2003;34:1826.)
© 2003 American Heart Association, Inc.

Original Contributions

Editorial Comment—Routine Thrombophilia Testing in Stroke Patients Is Unjustified

Stroke Unit, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
Thrombosis and Haemophilia Service, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The whole area of laboratory screening for thrombophilias in stroke patients is shrouded in uncertainty as to which (if any) patients to screen, what laboratory tests to order, how to interpret the results, and when to change therapy. To answer these questions, it is important to define the conditions and to consider their prevalence in the community and in patients with venous thromboembolism (VTE) and stroke; the likely attributable risk of stroke for each, if any, of the thrombophilias; the costs of the laboratory tests for thrombophilias; and the effectiveness of the results of testing in optimizing patient management and outcome.

	What Are the Thrombophilias?

 
There is no internationally accepted definition of thrombophilia, but the term is commonly used to describe disorders of the hemostatic mechanisms that are likely to predispose to thrombosis.¹ Thrombophilia may be inherited (deficiency of protein C, protein S, or antithrombin; activated protein C resistance resulting from the factor V Leiden mutation; the prothrombin gene [20210 G/A] mutation; and dysfibrinogenemia), acquired (lupus anticoagulant [LA] and anticardiolipin [ACL] antibodies), or mixed or unknown (high levels of coagulation factor VIII, IX, or XI; high levels of thrombin activatable fibrinolysis inhibitor).

	How Common Are the Thrombophilias?

 
At least 1 thrombophilic disorder is present in 10% to 15% of the white Western European population,² and as highlighted in the study by Jerrard-Dunne et al³ in this issue of Stroke, the distribution of blood concentrations of coagulation proteins, and thus diagnostic criteria and prevalence of thrombophilias, varies among other well-defined ethnic groups such as black Caribbeans and black Africans.³ . . . [Full Text of this Article]

This article has been cited by other articles:

				R. K. Patel and R. Arya Tests for Hereditary Thrombophilia Are of Limited Value in the Black Population Stroke, December 1, 2003; 34 (12): e236 - e236. [Full Text] [PDF]